About this trial
The pharmacological treatment strategy is then tailored to the underlying hemodynamic phenotype of each patient. That is, rather than applying a one-size-fits-all treatment for all patients, therapy is tailored to the specific characteristics of how the cardiovascular system functions in each patient (e.g., whether the problem is more related to blood volume, vascular resistance, cardiac output, etc.). The goal is to personalize therapy to more effectively treat hypertensive states of pregnancy.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age greater than or equal to 18 years
Women with singleton and twin pregnancies complicated by hypertensive states of pregnancy.
Disqualifiers
Minors under 18 years of age.
Women with mental disabilities.
Major congenital fetal anomaly.
Trial population
Pregnant patients undergoing regular hospital follow-up
Trial design
Other
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Prolongation of at least one week of gestation in pregnancy complicated by hypertensive state of pregnancy with antihypertensive therapy guided by hemodynamic phenotypes
Number of weeks of pregnancy
Sponsors and contacts
Click on the lead sponsor to view all of their trials.